How to Read a PMA Annual Report

A PMA approval letter closes out the review, not the manufacturer’s obligations. Every year after that — for as long as the approval stands — the periodic report is the one scheduled moment where a reviewer who isn’t looking at this device day to day gets to check whether it’s still the device FDA actually approved.

In brief

21 CFR § 814.84 requires a periodic report on the interval FDA sets in the approval order — commonly annual — for as long as the PMA stays in effect, not just through the first year on the market.
It isn’t a supplement. No new approval is being requested. It’s a status report: what changed, what came up, and what’s still open from any post-approval study required as a condition of approval.
The required content covers device or labeling changes that didn’t rise to the level of a supplement, a summary of new safety and effectiveness information the sponsor has — published or not — and progress against any post-approval study commitment.
The IND annual report is the closest pharma equivalent — the same once-a-year synthesis, at a different program stage: that one argues a study should keep running, this one shows a marketed device still matches its file.

What the regulation actually asks for

21 CFR § 814.84 sets the content: a description of any changes to the device or its labeling made without a supplement — the kind the regulation doesn’t require prior approval for, not the kind that does — a summary of unpublished data and reports bearing on the device’s safety or effectiveness that the applicant hasn’t already reported to FDA, plus a bibliography of anything published, and, where the approval order required one, an update on any post-approval study. None of this is raw data submitted for the first time. Almost all of it should already exist somewhere in the manufacturer’s own records, in the risk management file or the complaint trending that feeds it. The periodic report is where someone has to pull those threads into one document a reviewer who isn’t inside the company can actually follow.

Why the roll-forward habit is the risk

The easiest way to produce a periodic report is to start from last year’s and update the dates. That habit is also how drift survives past the year it started: a labeling change made for a good reason in March gets summarized correctly in this year’s report and then never mentioned again, even though it’s still true two years later and worth someone re-checking against what the device now actually does. Reading last year’s report before writing this year’s — not as a template, but as a claim to re-verify — is what keeps the document doing the job it’s actually for: catching a device that has quietly moved away from its approved file before an inspector or a competitor does.

Where this goes wrong

Treating it as a template rather than a re-verification

Copying last year’s report forward with only the dates updated, so a change from two cycles ago never gets checked against what’s true now.

Reporting a change without reconciling it against the file

Naming a device or labeling change in the narrative without confirming the design history file and the current labeling actually agree with what the report says happened.

Waiting for a supplement trigger to notice labeling drift

Assuming that if a change didn’t require a supplement, it doesn’t need tracking anywhere else either — the periodic report is often the only place it’s on record at all.

None of this changes what the regulation technically requires. It changes who benefits from reading the report closely: the same people who’d be asked to explain a labeling mismatch to an inspector are the ones positioned to catch it first, in their own document, before anyone else does.

Sources & further reading

21 CFR § 814.84 — Periodic Reports ecfr.gov
Regulatory Academy — How to Read an IND Annual Report regulatoryacademy.com
Regulatory Academy — How to Read a PMA Summary of Safety and Effectiveness Data regulatoryacademy.com
Regulatory Academy — How to Read a Risk Management File regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.